Business Wire

FL-KNOWBE4

Share
KnowBe4 Finds State and Local Governments Struggle to Defend Against Ransomware and Business Email Compromise

KnowBe4, the provider of the world’s largest security awareness training and simulated phishing platform, released a new report showing the continued impact cyber crime is having on state and local governments entitled “The Economic Impact of Cyber Attacks on Municipalities”.

KnowBe4’s report details the financial costs, reputational effects, level of public trust and other impact cyber attacks have on municipalities. The report breaks down the impact cyber attacks have into five target areas: the average financial loss from state and local governments, the denial of service to citizens due to financial loss, the frequency/types of attacks and the risk of recurring attacks, the challenge of allocating capital to prevent attacks and the decline of economic investment in municipalities.

Additionally, the new reports revealed ransomware continues to plague municipalities in all industry sectors. Business email compromise (BEC) attacks were also proven to be one of the most lucrative forms of cyber attacks in 2022, generating billions of dollars lost across all sectors and increasing across all sectors by 175%, with an 81% surge in 2022. State and local governments are particularly vulnerable to these attacks due to government transparency laws which allow cyber criminals to more easily tailor their attack to the victim.

Key findings from the report include:

  • Many municipality cybersecurity budgets are underfunded or do not exist at all. According to the National Association of State Chief Information Officers (NASCIO), most state cybersecurity budgets are between 0% and 3% of their overall IT budget. Additionally, only 18 states have a cybersecurity budget line-item and only 16% of states reported a budget increase of 10% or greater since 2018.
  • The 2022 IC3 Report reveals that in 2022, BEC attacks generated a total of $2,742,354,049 in losses across sectors, an increase of $346 million from 2021, and $875 million from 2020.
  • There are 1.7 million ransomware attacks every day, which means 19 ransomware attacks every second. Cybersecurity Ventures predicts that by 2031, ransomware will cost victims $265 billion annually, and it will attack a business, consumer or device every 2 seconds.
  • Ransomware attacks on state and local governments last an average of 7.3 days. Down time alone generates an average loss of $64,645.

In addition to state and local governments, educational institutions are also prime targets and victims of cyber attacks. In 2022, ransomware impacted nearly double the amount of universities and colleges than it did in 2021. Moody’s, which began tracking school districts in 2018, reports that the rates at which school districts are targeted has increased “exponentially”.

“Despite the many statistics and reports that detail the devastating losses caused from ransomware, business email compromise and other cyber attacks, many municipalities still find themselves underprepared for these threats,” said Stu Sjouwerman, CEO, KnowBe4. “Regardless of budget or size, the best way for all industry sectors to defend themselves against the threat of cyber attacks is to educate employees with new-school security awareness training and learn to develop a healthy skepticism of messages from even known contacts. Major municipality targets such as local and state governments and education and healthcare institutions are the backbone of civil service and society. Trained employees are essential to support IT teams, strengthen security culture and create a human firewall as the last line of defense to protect industries across the board, especially the municipality sectors we rely on everyday.”

To download The Economic Impact of Cyber Attacks on Municipalities report, visit https://www.knowbe4.com/hubfs/Economic-Impact-of-Cyber-Attacks-on-Municipalities.pdf.

To download KnowBe4’s Ransomware Hostage Rescue Manual, visit https://info.knowbe4.com/ransomware-hostage-rescue-manual-0.

About KnowBe4

KnowBe4, the provider of the world’s largest security awareness training and simulated phishing platform, is used by more than 56,000 organizations around the globe. Founded by IT and data security specialist Stu Sjouwerman, KnowBe4 helps organizations address the human element of security by raising awareness about ransomware, CEO fraud and other social engineering tactics through a new-school approach to awareness training on security. Kevin Mitnick, an internationally recognized cybersecurity specialist and KnowBe4's Chief Hacking Officer, helped design the KnowBe4 training based on his well-documented social engineering tactics. Tens of thousands of organizations rely on KnowBe4 to mobilize their end users as their last line of defense.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230329005253/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in

Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release

Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release

First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye